Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07823348) titled 'JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver Cancer' on Sept. 11.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label).
Primary Sponsor: Shanghai Junshi Bioscience Co., Ltd.
Condition:
Hepatocellular Carcinoma
Intervention:
Drug: JS207
Drug: JS007
Drug: Toripalimab
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: October 8, 2026
Target Sample Size: 560
Countries of Recruitment:
China
To know more, visit https://clini...